GlassScriptPhysician profile
Ali Sheybani
NPI 1427006824
$3,800.88
in general payments reported to CMS, 2019-2025
30 companies · $941 in 2025
The $941 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $39.60 · 2021: $261 · 2022: $465 · 2023: $753 · 2024: $921 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,595.85 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $977.07 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $362.54 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $349.28 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $339.68 | 2021-2025 | Breztri, Airsupra, Fasenra |
| Abbvie INC. | $161.76 | 2021-2023 | Qulipta |
| Optinose US, INC. | $158.33 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $139.25 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $135.26 | 2024-2025 | |
| Lilly USA, LLC | $128.72 | 2019-2025 | Ebglyss |
| Philips North America LLC | $120.79 | 2019 | |
| Glaxosmithkline, LLC. | $112.89 | 2022-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Pfizer INC. | $101.67 | 2023-2025 | |
| Novo Nordisk INC | $94.58 | 2021-2025 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $90.86 | 2019-2021 | |
| Genzyme Corporation | $71.07 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $60.29 | 2024 | Dupixent |
| Ardelyx, INC. | $57.66 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.42 | 2021-2022 | |
| Leo Pharma INC. | $51.28 | 2024 | Adbry |
| Shield Therapeutics INC | $28.16 | 2023 | Accrufer |
| Paratek Pharmaceuticals, INC. | $25.36 | 2025 | Xhance |
| Ionis Pharmaceuticals, INC. | $25.05 | 2025 | Dawnzera |
| Biohaven Pharmaceutical Holding Company LTD. | $23.68 | 2022 | |
| Radius Health, INC. | $22.86 | 2024 | |
| Sanofi-Aventis U.S. LLC | $22.29 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.12 | 2020 | |
| Vertiflex, INC. | $19.06 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Dexcom, INC. | $14.56 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Sheybani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.